33results about How to "Maximizes delivery" patented technology

Marine LNG carrier and method of operating the marine LNG carrier. The LNG carrier carries LNG in at least one tank. Gas composed of evaporated LNG within the at least one tank is removed. The gas is fed to at least one gas consuming prime mover of the LNG carrier. Power is provided with the at least one gas consuming prime mover. This Abstract is not intended to define the invention disclosed in the specification, nor intended to limit the scope of the invention in any way.

A modified Fletcher-Suit tandem tube applicator includes a balloon which can be inflated to both positionally secure the applicator within the vaginal canal and to distend the confronting vaginal wall thereby increasing the distance of such tissue from the radioactive source contained in the tandem tube of applicator and correspondingly reducing radiation damage to nearby tissues and organs such as the rectum and bladder.

The present invention provides bioerodible, water-soluble pharmaceutical carriers for ocular (e.g., transconjunctival or transcorneal) delivery of pharmaceuticals for either systemic or local therapy.

An object of the invention is to provide a method for delivery of macromolecules into biological cells in the tissues of a patient and includes the steps of: (a) providing electrodes (16) in an electrode assembly (12), wherein the electrodes have fixed electrode surfaces (42) which are coated with at least one static layer of electrode releasable molecules (44) to be delivered; (b) providing a waveform generator (15) for generating electric fields; (c) establishing electrically conductive pathways between the electrodes (16) and the waveform generator (15); (d) locating the electrodes (16) such that the biological cells are situated therebetween, and (g) providing electric fields in the form of pulse waveforms from the waveform generator (15) to the electrodes (16), such that molecules in the at least one static layer of the electrode releasable molecules (44) on the electrodes (16) are delivered into the biological cells. The electrode releasable molecules (44) can be either electric field separable molecules and/or solvent separable material. Another object of the invention is to provide an apparatus for carrying out the method of the invention. The static-coated electrode assembly (12) can be provided in a sterile package (24), from which the electrode assembly (12) is removed prior to use. The statically-coated electrode assembly (12) can be in a form of a disposable assembly (12) which is removable and replaceable from an electrode assembly holder (13).

A lamp including a reflective portion is utilized in a fluid purification system to maximize the light delivery to a photocatalytic coating that oxidizes gaseous contaminants that adsorb onto the surface to form carbon dioxide, water, and other substances. An ultraviolet light source positioned proximate to the honeycomb activates the titanium dioxide coating. In one example, the reflective portion is a reflective coating. Light directed out of the non-reflective portion of the lamp travels towards the honeycomb and absorbs onto the photocatalytic coating. Light directed towards the reflective portion on the lamp is reflected off the surface of the reflective portion and passes through the non-reflective portion of the lamp to also absorb onto the photocatalytic coating. The reflective portion reflects light towards the honeycomb that would otherwise be misdirected away from the honeycomb, increasing efficiency of the fluid purification system.

The present invention includes compounds that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound and/or composition of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound and/or composition of the invention.

An energy transduction and conservation system has a rotatable primary driving arrangement and a rotatable driven arrangement, the driving and driven arrangements cooperating through an energy storage arrangement. The driving arrangement supplies energy to the energy storage arrangement through a one-way driving system which blocks energy release from the energy storage arrangement back to the driving arrangement. Relative rotation of the driving arrangement is transferred to the energy storage arrangement through a first releasable clutch acting on a one-way rotatable hub whereby energy stored is released only through the driven arrangement. A further one-way clutch is actuated by a differential angular rotational speed to disconnect the first releasable clutch and drive the hub at the same time the energy storage arrangement drives the driven arrangement. The first releasable clutch includes release levers pivotally mounted to release the clutch and allows the inner body to rotate in the normally locking direction.

A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.

A formulation comprised of particles which may be in groups and are comprised of a biocompatible polymer and an antimicrobial drug for controlled release of the drug is disclosed. The particles may be in an aqueous solution comprising thrombin and be dispersed in a gel. The formulation is administered to an area such as an open wound having an orthopedic implant therein and provides a therapeutically effective level of drug to the patient over therapeutically effective period of time.

A method for providing anesthesia to a subject having a wound, such as a laceration, a surgical incision, an ulcer, an abrasion or a burn, said method comprising the step of applying topically to the wound a composition comprising: at least one local anesthetic agent; a hydrophilic or hydroalcoholic gelling agent; an antiseptic agent; a vasoconstrictor; and a detectable marker such as a food dye, wherein when the composition is topically applied to the wound of the subject the presence of the anesthetic agent on the subject is indicated by the detectable marker. The method has been developed primarily for anaesthetizing open wounds of animals, particularly those caused by husbandry procedures.

A method and apparatus is disclosed for separating an amount of a perfluoroalkyl or polyfluoroalkyl substance (PFAS) from water which is contaminated with the substance. The method comprises the steps of: admitting an amount of the water, which includes an initial concentration of the substance, into a chamber via an inlet thereinto, and introducing a flow of gas into the chamber. The introduced gas induces the water in the chamber to flow, and produces a froth layer which is formed at, and which rises above, an interface with the said flow of water and of introduced gas in the chamber. The froth layer includes an amount of water, and also a concentrated amount of the substance in comparison compared with its initial concentration. The step of removal of at least some of the froth layer from an upper portion of the chamber occurs.

A method and system for improved environmental remediation. A method comprising establishing an initial remediation protocol; applying at least one initial motive force according to the initial remediation protocol; monitoring the effect on the site resulting from the application of the at least one initial motive force; modifying the remediation protocol to improve the performance of the remediation using information gleaned from the monitoring of the site; applying at least one motive force according to the modified remediation protocol; and repeating monitoring, modifying, and applying in a more or less continuous fashion until the remediation is complete.

A Laser Bar Coupler With Improved Brightness of the present invention includes a laser diode array having a number of spaced-apart laser elements, or diodes, each emitting laser radiation. The typical laser diode array laser elements are rectangular in shape, and linearly spaced apart along an axis with the long dimensions of the element along the axis. A number of optical fibers, or waveguides, each having an initially rectangular cross-section are placed adjacent each laser element and sized horizontally and vertically to approximate the rectangular dimensions of the laser element. The proximity and similar sizing of the input end of the rectangular optical fiber to the laser element provides for the near total reception of the optical energy from the laser element into the fiber. As the rectangular fibers extend away from the laser diode array, the optical fibers taper along the slow axis from its input having a dimension approximately the width of the laser emitter, to an output having a dimension which is less than the first dimension. Using this tapering technique, the optical power available at the output has a higher optical density, a significant brightness increase, and has a lower manufacturing cost than alternative and more complicated designs.

The present invention includes pyrimido[5,4-d]pyrimidines that are useful in the prevention and/or treatment of breathing control diseases or disorders in a subject in need thereof. The present invention also includes a method of preventing and/or treating a respiratory disease or disorder in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention. The present invention further includes a method of preventing destabilization or stabilizing breathing rhythm in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of at least one compound of the invention.

Photovoltaic devices where glass substrates have a composition where (RO+M₂O)/Z₂O₃ is greater than 1. This ratio may affect sodium out-flux from the glass substrate and into the CIGS layer or the Mo layer or both.